



Food and Drug Administration
OFFICE OF CRIMINAL INVESTIGATIONS
REPORT OF INVESTIGATION

REPORTING OFFICE: San Francisco Resident Office
DOCUMENT NUMBER: 169653
CASE NUMBER: 2010-SFC-735-0280
RELATED CASE NUMBER: (b) (7)(E)
TYPE OF CASE: 735.100, DIETARY SUPPLEMENTS - CDER
CASE TITLE: PRIMORDIAL PERFORMANCE
CASE AGENT: (b) (7)(F)
INVESTIGATION MADE AT: Oakland, CA
INVESTIGATION MADE BY SA (b) (7)(F)
REPORTING PERIOD: FROM: 04/21/2010 TO: 09/07/2010
STATUS OF CASE: Continued

SYNOPSIS: Undercover purchase of PRIMORIDAL PERFORANCE 5 "pro-hormone" products; Receipt of UC purchase, inventory and forwarding to FCC; (b) (7)(E)

RESTRICTED INFORMATION

This report is furnished on an official need-to-know basis and must be protected from dissemination which might compromise the best interests of the Food and Drug Administration, Office of Criminal Investigations. This report shall not be released in response to a Freedom of Information Act or Privacy Act request or disseminated to other parties without prior consultation with the FDA Office of Criminal Investigations.

UNAUTHORIZED RELEASE MAY RESULT IN CRIMINAL PROSECUTION

REPORT SUBMITTED BY: (b) (7)(F), Special Agent, DATE: 09/07/2010

REPORT APPROVED BY: Thomas W. Emerick, Special Agent in Charge, DATE: 09/09/2010

DISTRIBUTION: ORIG: SFC
CC: AD-IOD
CC: LAC

## 1. INTRODUCTION:

This case originated after the February 8, 2010, receipt of information from the United States Anti-Doping Agency (USADA) about an email solicitation from PRIMORDIAL PERFORMANCE on the sale of a new product called Superdrone. The email indicates that PRIMORDIAL PERFORMANCE's Superdrone is a "Superdrol-clone" and contains the designer anabolic steroid methyldrostanolone. Superdrol (aka methyldrostanolone, aka methasteron) is a designer anabolic steroid <sup>(b) (7)(E)</sup>

<sup>(b) (7)(E)</sup>

Reference is made to the Report of Investigation (ROI), covering the time period from February 8, 2010, through April 20, 2010.

## 2. DETAILS OF INVESTIGATION:

On May 4, 2010, SA <sup>(b) (7)(F)</sup> placed an undercover purchase for each of PRIMORDIAL PERFORMANCE's five listed "pro-hormone" products, AndroHard, Formestane-LV, 1-T Liqua-Vade, Turinabol-LV and Dermacrine Liqua-Vade, through the PRIMORDIAL PERFORMANCE website at WWW.PRIMORDIALPERFORMANCE.COM. <sup>(b) (7)(E)</sup>

The invoice detailing this purchase is Attachment 1. The shipment was directed to <sup>(b) (7)(E)</sup>

Continuing on May 12, 2010, SA <sup>(b) (7)(F)</sup> received the aforementioned order of the five PRIMORDIAL PERFORMANCE "pro-hormone" products at <sup>(b) (7)(E)</sup>.

Continuing on June 18, 2010, SA <sup>(b) (7)(F)</sup> inventoried the five PRIMORDIAL PERFORMANCE "pro-hormone" products received and retrieved <sup>(b) (7)(E)</sup> on May 12, 2010. The following items were inventoried on CIE 152909: 1 sealed 4.2 oz. bottle of PRIMORDIAL PERFORMANCE Formestane with syringe plunger, 1 sealed 4.2 oz. bottle of PRIMORDIAL PERFORMANCE Turinabol with syringe plunger, 1 sealed 8.2 oz. bottle of PRIMORDIAL PERFORMANCE Dermacrine with syringe plunger, 1 sealed 8.2 oz. bottle of PRIMORDIAL PERFORMANCE Liqua-Vade with syringe plunger and 1 sealed 8.2 oz. bottle of Andro-Hard with syringe plunger.

Continuing on July 1, 2010, SA <sup>(b) (7)(F)</sup> released the above items on CIE 152909 to SFC evidence custodian <sup>(b) (7)(F)</sup>, who forwarded the items to the FCC for testing and analysis on July 2, 2010. Later, SA <sup>(b) (7)(F)</sup> received a copy of the chain of custody log indicating that the items on CIE 152909 were received by the FCC on July 6, 2010.

Continuing on July 6, 2010, SA <sup>(b) (7)(F)</sup> inventoried several other items received with the PRIMORDIAL PERFORMANCE order made on May 4, 2010. The following items were inventoried on CIE 152929: Shipping box, packaging material and invoice relating to the purchase of PRIMORDIAL PERFORMANCE products Andro-Hard, Formestane-LV, 1-T Liqua Vade, Turinabol-LV and Dermacrine Liqua-Vade. All items inventoried on CIE 152929 were received by SFC evidence custodian

(b) (7)(F) on July 30, 2010, and placed into the FDA-OCI SFC evidence repository.

(b) (7)(E)

As noted in the report of investigation dated April 20, 2010, PRIMORDIAL PERFORMANCE CEO ERIC PORTRATZ made a message board posting on the PRIMORDIAL PERFORMANCE website on December 23, 2009, advertising the pending sale of "Tren Tablets" to be available on December 27, 2010, (b) (7)(E)

Additionally, as also detailed in the report of investigation dated April 20, 2010, PORTRATZ made a previous posting to the message forum on the PRIMORDIAL PERFORMANCE website on August 20, 2009, detailing that PRIMORDIAL PERFORMANCE would immediately discontinue its sale of "Tren" (b) (7)(E)

### 3. JUDICIAL ACTION:

None this reporting period

### 4. DISPOSITION OF EVIDENCE, CONTRABAND, AND PERSONAL PROPERTY:

Evidence obtained during this reporting period was inventoried on CIE 152909 (b) (7)(E). Evidence on CIE 152909 was transferred and forwarded to FCC for testing and analysis. Evidence on 152929 is being retained at the San Francisco Resident Office evidence repository.

### 5. STATUS OF INVESTIGATION:

Continued

### 6. SUSPECTS/DEFENDANTS/OTHER:

PRIMORDIAL PERFORMANCE  
ERIC POTRATZ

(b) (6), (b) (7)(C)

WWW.PRIMORDIALPERFORMANCE.COM

### 7. ATTACHMENTS:

1-Invoice from PRIMORDIAL PERFORMANCE detailing the purchase of 5 PRIMORDIAL PERFORMANCE "pro-hormone" products.

2-(b) (7)(E)